Understanding and treating lung tumors that resist current therapies
In vivo imaging of mitochondria structure and function in therapy resistant lung tumors
This research aims to find better ways to diagnose and treat non-small cell lung cancer, especially when it has become resistant to other treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11160536 on NIH RePORTER |
What this research studies
We are working to discover new diagnostic tools and treatment strategies for non-small cell lung cancer (NSCLC), focusing on tumors that have developed resistance to existing therapies. Our approach involves using a new type of PET scan tracer to identify specific metabolic patterns in these resistant tumors. By understanding how these cancer cells use energy, we hope to develop new treatments that specifically target these metabolic weaknesses. This could lead to more effective ways to fight lung cancer, particularly for patients whose tumors no longer respond to standard care.
Who could benefit from this research
Good fit: This research is most relevant to patients with non-small cell lung cancer, particularly those whose tumors have specific KRAS/LKB1 or EGFR mutations and have become resistant to current treatments.
Not a fit: Patients without non-small cell lung cancer or those whose tumors are not resistant to therapy may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to new diagnostic tests and targeted treatments that improve survival for patients with therapy-resistant non-small cell lung cancer.
How similar studies have performed: This project proposes a novel metabolic diagnostic and a different approach to overcoming therapy resistance, building on existing knowledge but exploring new avenues.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Shackelford, David B — University of California Los Angeles
- Study coordinator: Shackelford, David B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.